Use of cpg as an adjuvant for hiv vaccine
CA 2376992 A1 · Owner: Smithkline Beecham Biologicals S.A. · Inventors: Garcon, Nathalie; Voss, Gerald
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A vaccine formulation for the prevention or amelioration of HIV infection in humans is provided. The vaccine comprises an HIV antigen especially a protein , which comprises Nef and/or Tat of HIV and an immunostimulatory CpG , oligonucleotide. Methods for making the vaccine formulation of the invention are described. Patients may also be treated by pre-administration of the CpG oligonucleotide prior to administration of the HIV antigen.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 28, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 28, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 28, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.